ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Fujifilm to restart Avigan COVID-19 trials in Japan

Drug has already been approved in India and Indonesia for emergency use

Flu-fighting drug Avigan may see a second life in Japan as a COVID-19 treatment with a new trial set to begin in April.   © Reuters

TOKYO -- Japan's Fujifilm Holdings will restart a clinical trial for its flu-fighting drug Avigan to treat Japanese COVID-19 patients as early as April, Nikkei has learned, giving new life to the medication that had been seen as a potential game changer in the early stages of the pandemic.

Avigan, which has already been approved in India and Indonesia for emergency use to treat COVID-19 patients, could not win the green light in Japan last year after a health ministry expert board postponed a decision in December. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more